In Segment C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will receive treatment right until disease progression or the participants are unable to tolerate the study drugs. There might be increased treatment load for members in this trial in comparison https://abbv-744-brd4-inhibition92356.bloggerswise.com/39141875/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed